In this week’s View, Dr. Eagle highlights a study comparing a proteomics-based risk model to a traditional risk factor model in predicting recurrent atherosclerotic events in two observational cohorts, He also discusses the prevalence of noncalcified and calcified plaque in symptomatic adults and its association with cardiovascular disease (CVD) events across the low-density lipoprotein cholesterol (LDL-C) spectrum. And finally, Dr. Eagle reviews the effects of empagliflozin on heart failure hospitalizations across the full range of left ventricular ejection fractions.

Clinical Topics: Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Prevention, Atherosclerotic Disease (CAD/PAD), Homozygous Familial Hypercholesterolemia, Acute Heart Failure, Heart Failure and Cardiac Biomarkers, Interventions and Coronary Artery Disease, Interventions and Imaging, Angiography, Nuclear Imaging

Keywords: EaglesEyeView, Atherosclerosis, Biomarkers, Cardiometabolic Risk Factors, C-Reactive Protein, Heart Disease Risk Factors, Inflammation, Interleukin-6, Secondary Prevention, Stroke, Coronary Angiography, Coronary Artery Disease, Diagnostic Imaging, Dyslipidemias, Hypercholesterolemia, Myocardial Infarction, Myocardial Ischemia, Plaque, Atherosclerotic, Primary Prevention, Adrenergic beta-Antagonists, Angiotensins, Cardiomyopathies, Heart Failure, Hospitalization, Mineralocorticoid Receptor Antagonists, Natriuretic Peptides, Sodium-Glucose Transporter 2 Inhibitors, Stroke Volume, Ventricular Function, Left

< Back to Listings